Brief: Innovation Reports Data From Lab Supporting Brilacidin As Potential Treatment For SARS-CoV-2
15/09/2020 14:17
Sept 15 (Reuters) - Gilead Sciences Inc GILD.O :
* INNOVATION PHARMACEUTICALS - REPORTS ADDITIONAL DATA
FROM LAB
SUPPORTING BRILACIDIN AS POTENTIAL TREATMENT FOR SARS-COV-2
* INNOVATION PHARMACEUTICALS INC - LABORATORY TESTING OF
BRILACIDIN FOR COVID-19 IN COMBINATION WITH REMDESIVIR REDUCES
VIRAL LOAD BY NEARLY 100%
Source text for Eikon: ID:nGNX3Fsf9R
Further company coverage: GILD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovation Pharmaceuticals
See all newsBrief: Innovation Pharmaceuticals Announces New Milestone At Beamed On Track To File 510(K) Submission To FDA In Q2 2024
Brief: Innovation Pharmaceuticals Provides Update On US Patent Applications Covering Use Of Brilacidin In Inflammatory Bowel Diseases, Coronaviruses And Fungal Diseases
Brief: Innovation Pharma Reports Enrollment In Phase 2 Trial Of Brilacidin For COVID-19 Tops 70%
Brief: Innovation Pharma Surpasses 50% Enrollment In Phase 2 Clinical Trial Of Brilacidin For COVID-19
Brief: Innovation Pharma Completes Interim Safety Data Review